Pfizer Inc. (NYSE:PFE) Shares Sold by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,259 shares of the biopharmaceutical company’s stock after selling 7,411 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Pfizer were worth $698,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. RB Capital Management LLC lifted its holdings in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. lifted its holdings in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank lifted its holdings in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC lifted its holdings in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in shares of Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

NYSE PFE opened at $25.99 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $27.11 and its two-hundred day moving average is $28.68. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The stock has a market capitalization of $147.17 billion, a price-to-earnings ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.